Thus, once an individual achieves sustained weight loss (ie, achieving maximum weight loss for a certain period, such as a few months) using an GLP-1/IM therapy at recommended doses, an option to switch to an alternative weight-maintenance program—incorporating elements such as lower-cost medications (than full-dose GLP-1s/IMs), a behavioral health program, and nutrition support—has the potential to more efficiently reallocate resources devoted to obesity management efforts. The gene discussed is GLP1R; the disease is obesity disorder.